Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895622 · ClinicalTrials.gov registry record · Phase 2
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
- 20
- Study locations
NCT00895622: Completed Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Radiation Therapy Oncology Group.
NCT00895622 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 244 participants, above the 178-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00895622, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy, may kill more tumor cells and cause less damage to normal tissue. It is not yet known whether observation is more effective than radiation therapy in treating patients with meningioma. PURPOSE: This phase II trial is studying observation to see how well it works compared with radiation therapy in treating patients with grade I, grade II, or grade III meningioma.
Primary Outcome
Progression was determined by central review of magnetic resonance imaging (MRI) exams and is defined as an increase in measurable tumor of greater than 20% in any diameter, or as new nodular enhancement in patients with no measurable tumor on initial postoperative imaging. In the absence of neurologic progression (NP), suspected imaging progression of less than 5 mm (maximum diameter) must be confirmed on two successive follow-up MRI studies, a minimum of 3 months apart. NP is defined as a new
Conditions Studied
Interventions
- RADIATION 54 Gy radiotherapy
- RADIATION 60 Gy radiotherapy
Study Locations (20)
Arizona
- Arizona Oncology Services Foundation - Phoenix
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic Scottsdale - Scottsdale
Georgia
- Emory Crawford Long Hospital - Atlanta
- Winship Cancer Institute of Emory University - Atlanta
- Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center - Savannah
Kansas
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center - Kansas City
- Kansas City Cancer Centers - Southwest - Overland Park
- CCOP - Kansas City - Prairie Village
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- University of Florida Shands Cancer Center - Gainesville
- Baptist-South Miami Regional Cancer Program - Miami
Connecticut
- Yale Cancer Center - New Haven
Idaho
- Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center - Boise
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2009-06 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 2 |
What the finished NCT00895622 record still lists
NCT00895622 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, above the 178-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (37% higher).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which 54 Gy radiotherapy is the first listed.
NCT00895622 names 20 study sites across 12 states, led by Arizona, Georgia, Kansas.
Frequently Asked Questions
What is clinical trial NCT00895622 about?
NCT00895622 is a clinical study titled "Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma". RATIONALE: Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as 3-dimensional conformal radiation therapy and intensity-modulated radiation therap...
What is the current status of trial NCT00895622?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2009-06. Estimated completion is 2023-08-15.
What conditions does trial NCT00895622 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00895622?
The interventions under investigation include: 54 Gy radiotherapy (RADIATION), 60 Gy radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT00895622?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00895622 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00895622's enrollment target sits among peer trials
244 9th of 45 higher than 37 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
COMPLETED · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia